Developmental pathway for potent V1V2-directed HIV-neutralizing antibodiesNicole A. Doria‐Rose, John R. Mascola|Nature|2014Cited by 749
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M. El Sahly, Jacqueline M. Miller, Lindsey R. Baden et al.|New England Journal of Medicine|2021Cited by 661
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, John Hural et al.|New England Journal of Medicine|2021Cited by 540
Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged MonkeysNorman L. Letvin, Gary J. Nabel, John R. Mascola et al.|Science|2006Cited by 367
Next-generation influenza vaccines: opportunities and challengesChih‐Jen Wei, Gary J. Nabel, Michelle C. Crank et al.|Nature Reviews Drug Discovery|2020Cited by 333